Seres Therapeutics press release (MCRB): Q2 EPS of $0.47 may not be comparable to consensus of -$2.19. – Gain on Sale of the VOWST Business recognized in the second quarter of 2026 arising from the Milestone Termination Payment due from Nestlé. – Revenue of $0.74M beats by…
Seres Therapeutics EPS of $0.47, Revenue of $0.74m Beats by $0.56m
Seres Therapeutics press release (MCRB): Q2 EPS of $0.47 may not be comparable to consensus of -$2.19. - Gain on Sale of the VOWST Business recognized in the second quarter of 2026 arising from the Milestone Termination Payment due from Nestlé. - Revenue of $0.74M beats by...</p